HeartBeam (NASDAQ: BEAT) has announced a strategic reorganization designed to accelerate execution, expand global market reach, and improve capital efficiency as it advances commercialization of its cardiac monitoring technology. The company, which focuses on transforming detection and monitoring of critical cardiac conditions, said the new structure will streamline decision-making, improve accountability, and reduce costs.
Under the reorganization, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams. Former CEO Robert Eno will move into a consulting role. The company stated that its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection.
HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers, and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The company's 3D ECG platform is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities.
The announcement highlights HeartBeam's commitment to redefining the future of cardiac health management. The company holds over 20 issued patents related to its technology, which is the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG.
This reorganization comes as HeartBeam seeks to accelerate its global commercialization strategy, aiming to improve capital efficiency and expand its market reach. The move is expected to enable the company to better execute on its plans to partner with various entities and develop its technology for heart attack detection, which could have significant implications for cardiac care worldwide.
For more information, the full press release is available at https://ibn.fm/CTxXi. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
